Interim Analysis Suggests SARS-CoV-2 Vaccine Has 90% Efficacy RateNews
Pharmaceutical company Pfizer and biotechnology company BioNTech have announced the first interim efficacy data from a large-scale trial evaluating BNT162b2, a vaccine candidate developed against SARS-CoV-2. Their press release indicates a vaccine efficacy rate of ~90% seven days after a second dose of the vaccine is administered, however the data is yet to be published.Read more
Scientists Use Ancient DNA To Explore History of DogsNews
With the aid of genetic and statistical analyses, scientists were able to reconstruct the population history of prehistoric dogs, and investigate its relationship to that of humans, in a new study.Read more
Method Identifies Llama Nanobodies With "Ultra-High" SARS-CoV-2 Neutralization PotencyNews
In Science, researchers at the University of Pittsburgh School of Medicine describe a new method to extract tiny but extremely powerful SARS-CoV-2 antibody fragments from llamas, which could be fashioned into inhalable therapeutics with the potential to prevent and treat COVID-19.